<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257139</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2008-008372-13</org_study_id>
    <nct_id>NCT01257139</nct_id>
  </id_info>
  <brief_title>Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a &quot;Classical&quot; Strategy of Treatment Allocation, With an&quot;Optimized&quot; Strategy Allocating the Same Treatments</brief_title>
  <acronym>ESOGIA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <brief_summary>
    <textblock>
      This is a phase III randomized multicenter study involving subjects over 70 years of age with
      non small-cell lung cancer of IV and a PS of 0, 1 or 2, who have not previously received
      chemotherapy. The aim is to validate the use of a simplified geriatric scale (SGS) as a
      screening tool. If the SGS results are normal, the patient will be treated with dual-agent
      therapy based on platinum (carboplatin + pemetrexed if the histology is non epidermoid,
      carboplatin + gemcitabin if the histology is epidermoid), with no further geriatric
      assessment. When the SGS reveals abnormalities, a comprehensive geriatric evaluation (CGE)
      will be used to define two subpopulations on Balducci's fragility scale, who will receive
      either monotherapy (docetaxel) or best supportive care.

      The strategy based on the SGS will be compared with a treatment algorithm based on standard
      criteria (PS and age), with no specific geriatric assessment. The main endpoint is the time
      to treatment failure. The SGS is composed of the Charlson co-morbidity scale, functional
      assessment based on PS, Katz' ADL scale, Lawton's simplified IADL scale, simplified cognitive
      assessment with the mini-MMSE according to Schultz-Larsen, a geriatric depression scale (GDS
      5), and screening for a geriatric syndrome defined by the existence of dementia, repeated
      falls, and urinary and fecal incontinence. The SGS will be validated by comparison with the
      CGE, that will be administered systematically at enrollment. All the SGS items are included
      in the CGE.

      Secondary endpoints will be quality of life (measured with the LCSS and EuroQoL
      questionnaires), overall survival, the objective response rate, and toxicity. The
      investigators will also study the predictive power of nutritional indices such as the PINI
      and the Buzby score with respect to survival, the treatment response, and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to failure Defined from the date of inclusion to the date of documented progression Or death of any cause Or trial exit for toxicity considered unacceptable by the patient or by the investigator Or withdrawal of consent</measure>
    <time_frame>date of documented progression up to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">490</enrollment>
  <condition>Non Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>dual-agent therapy or docetaxel alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dual-agent therapy or docetaxel or best supportive care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual-agent therapy or docetaxel alone or best supportive care</intervention_name>
    <description>ARM B: (245 patients)
Treatment if the SGS screening test is negative:
non epidermoid tumor:
Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.
epidermoid tumor:
Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management.</description>
    <arm_group_label>dual-agent therapy or docetaxel or best supportive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically or histologically proven NSCLC(adenocarcinoma, epidermoid carcinoma,
             large-cell carcinoma) of stage IV with histologically or cytologically proven pleurisy
             or neoplastic pericarditis.

          -  No previous systemic chemotherapy for lung cancer.

          -  Presence of at least one measurable target lesion (RECIST rules) in a non irradiated
             region.

          -  Age strictly at least 70 years.

          -  PS 0, 1 or 2.

          -  Life expectancy sup 12 weeks.

          -  Creatinine clearance at least 45 ml per min with MDRD Formula (Modification in the
             Diet in Renal Disease).

          -  Normal hematologic function: absolute polymorphonuclear neutrophil count &gt; 1.5 . 109
             per l and or platelets sup 100 . 109/l, hemoglobin sup 9.5 g per dl

          -  Normal hepatic function: bilirubin inf 1.5 x normal, SGOT and SGPT inf 2.5 . normal.

          -  Patients with metastatic relapse (cytologically or histologically proven) of primary
             lung cancer in a non irradiated region, after surgical excision or local external
             radiotherapy.

          -  Prior irradiation is authorized if it involved less than 25 percent of the total bone
             marrow volume.

          -  Men must be surgically sterile or must accept the use of an effective contraceptive
             methodall along and until 6 months after the treatment period

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Other severe concurrent disorders that occurred during the prior six months before
             enrollment (myocardial infection, severe or unstable angor, coronarian or peripheric
             arterial bypass operation, NYHA class 3 or 4 congestive heart failure, transient or
             constituted cerebral ischemic attack, at least grade 2 peripheral neuropathy, stomach
             ulcer, erosive oesophagitis or gastritis, psychiatric or neurological disorders
             preventing the patient from understanding the trial, uncontrolled infections).

          -  Another previous or concomitant cancer, except for basocellular cancer of the skin or
             treated cervical cancer in situ, or appropriately treated localized lowgrade prostate
             cancer (Gleason score inf 6), unless the initial tumor was diagnosed and definitively
             treated more than 5 years previously, with no evidence of relapse.

          -  Bronchoalveolar or neuroendocrine or composite cancers

          -  Superior caval syndrome.

          -  Presence of symptomatic brain metastases.

          -  Peripheral neuropathies (grade sup 2).

          -  Performance status sup 2 (ECOG).

          -  A significant third liquid part (for example ascitis or pleural effusion) hat can't be
             controlled with drainage or other procedures before enrollment

          -  Impossibility to stop a treatment by aspirin (if the dose is more than 1.3 mg per day)
             or NSAI during 5 days (8 days for molecules with long period action like piroxicam

          -  Concurrent participation in another clinical trial.

          -  Definitive contraindication to steroids or folic acid and vitamin B12 if histology is
             non-epidermoid.

          -  All concurrent radiotherapy, except for local palliative bone radiotherapy.

          -  Concurrent administration of one or several other antitumor therapies. Recent
             vaccination for yellow fever (during the 30 days before enrollment)

          -  Psychological, familial, social or geographic difficulties preventing follow-up as
             defined by the protocol.

          -  Administrative or legal detention.

          -  Contraindication to the study drugs.

          -  Concurrent participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amien Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général de la Fontonne Antibes</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bastia</name>
      <address>
        <city>Bastia</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universaitaire de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Tonnerre</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos - Pontoise</name>
      <address>
        <city>Cergy Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Charleville mézières</name>
      <address>
        <city>Charleville Mézières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Draguignan</name>
      <address>
        <city>Draguignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Elbeuf</name>
      <address>
        <city>Elbeuf</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Gap</name>
      <address>
        <city>Gap</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A Mignot Le Chesnay</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Omar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Cluzeau</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Longjumeau</name>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Mantes La Jolie</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Martigues</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Farron</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Hôpital saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catalan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Périgueux</name>
      <address>
        <city>Périgueux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes Hospital University</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen Hôpital Boisguillaume</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Yves Le Foll</name>
      <address>
        <city>saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général Salon de Provence</name>
      <address>
        <city>Salon de Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>St Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées</name>
      <address>
        <city>Toulon Naval</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Font-Pre</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Touloues</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Villefranche sur Saone</name>
      <address>
        <city>Villefranche sur Saone</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To evaluate a geriatric scale designed to help with treatment</keyword>
  <keyword>allocation to dual-agent therapy based on platinum or to</keyword>
  <keyword>single-agent chemotherapy in elderly subjects with advancedstage</keyword>
  <keyword>NSCLC, based on the time to failure in the two arms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

